Pediatrix Medical Group (MD) concentration risks

The company's sole disclosed concentration is geographic: Texas accounted for approximately 32% of net revenue in 2025. By disclosed size this is a medium-share exposure, and its character is structural — the Texas footprint reflects where clinical and hospital relationships were established and expanded over time, making it an inherent feature of the physician services model rather than a transient or counterparty-specific dependency. There are no disclosed customer, supplier, regulatory, or product concentrations on record alongside this geographic exposure. The practical implication is that state-specific factors — Texas Medicaid reimbursement rates, hospital system consolidation in Texas, state insurance regulation, and the economic health of the Texas healthcare market — represent the primary risk channel through which this concentration would affect reported net revenue. At a medium-share, the exposure is meaningful but does not represent the majority of the revenue base, and results in the other markets not tied to Texas would provide partial offset in an adverse Texas-specific scenario. On balance, the disclosed concentration profile is limited and well understood. Texas revenue trends and Texas-specific healthcare reimbursement dynamics are the key variables to monitor within the single disclosed concentration exposure. The absence of any customer, supplier, or product concentration from the filing indicates that the geographic tilt is the primary lens through which to evaluate concentration risk for this company.

For the engine’s reasoning on MD’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.